Hanyu Pharmaceutical takes "worldly wisdom, benevolence is medicine" as the enterprise spirit, strictly follows the requirements of Drug Administration Law and good manufacturing practice, and adopts advanced management mode for drug production and quality control, and has been designated as a standard raw material supplier by China Institute for the Control of Pharmaceutical and Biological Products. Driven by science and technology, it has attracted a group of highly educated, high-quality and high-level elites, including postdoctoral and doctoral students studying in the United States. R&D personnel of Peptide Technology account for more than 30% of the total employees of the enterprise, and have established friendly and close cooperative relations with more than 30 research institutes at home and abroad. At present, it has obtained 7 national new drug certificates, 5 approvals for new drug clinical trials and more than 40 approvals for drug registration. Independent scientific and technological innovation has promoted the rapid development of enterprises. In the past three years, the company's annual sales revenue, profits and taxes and other economic indicators have doubled. In 2007, the company was selected as one of the "Top 0/00 Most Growing Science and Technology Enterprises in China" and won the "Shenzhen Science and Technology Innovation Award". In 2008, it cooperated strategically with Softbank Safran Asia Investment Fund and Shenzhen Innovation Investment Group, realizing the "strong alliance" between famous domestic and foreign investment institutions and domestic polypeptide pharmaceutical industry; It was named "Top 50 High-tech and High-growth Enterprises of Deloitte in China in 2008" and won the titles of "Shenzhen Science and Technology Innovation Award" and "Shenzhen Leading Enterprise in Independent Innovation Industry". In 2009, it was rated as one of the top 50 enterprises with the most investment value in Zero2IPO, a leading enterprise in Nanshan District, a famous brand in Shenzhen and a national high-tech enterprise.
Hanyu Pharmaceutical has the most advanced automatic polypeptide synthesis system and automatic purification system in the world, as well as production lines for small-volume injections, freeze-dried powder injections, tablets, hard capsules and granules. There are more than 40 kinds of preparations and raw materials mainly containing polypeptide drugs, including salmon calcitonin injection, desmopressin acetate injection, somatostatin for injection, thymopentin for injection, glucagon hydrochloride for injection, oxytocin for injection, omeprazole for injection, sodium ozagrel for injection and somatostatin for injection. Some products have been certified by DMF, a polypeptide raw material of FDA in the United States, and will become the first domestic enterprise to produce polypeptide drugs and enter the American market. Moreover, many large-scale distribution enterprises in the United States, Canada, Italy, India, Germany, Russia and other countries have become agents of Hanyu pharmaceutical products in the international market. On this basis, Hanyu Pharmaceutical will develop more, better and more sustainable follow-up products for the benefit of patients.